Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 4Recruiting 3Active not recruiting 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Head & Neck 2Gastrointestinal 2Breast 2Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Melanoma 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Carboplatin 134pembrolizumab 113Pemetrexed 94Cisplatin 88durvalumab 63Paclitaxel 60osimertinib 54Nivolumab 54Docetaxel 44atezolizumab 41Etoposide 30Radiotherapy 28Radiosurgery 26Gemcitabine 26Specimen Handling 24Ipilimumab 23Taxes 19Magnetic Resonance Spectroscopy 19amivantamab 16130-nm albumin-bound paclitaxel 16Drug Therapy 15Bevacizumab 15Radiation 14Platinum 14Immunoglobulin G 14Disulfides 14cemiplimab 13Crizotinib 13Cyclophosphamide 12Biopsy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × budigalimab × Thoracic × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT02988960 2026-01-09

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
163 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms

NCT03893955 2025-08-12

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

AbbVie

Phase 1 Active not recruiting
150 enrolled
BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡